AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
ราคาปิดก่อนหน้า
US$36.13
−US$0.05 · -0.14%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
ช่วงราคารายวัน
ปัจจุบัน US$36.13
ช่วง 52 สัปดาห์
ปัจจุบัน US$36.13
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ซื้อ
มูลค่า
73
ต่ำกว่ามูลค่า
ความเชื่อมั่น
63
เชิงบวก
ความเสี่ยง
44
ความเสี่ยงค่อนข้างสูง
โมเมนตัม
74
กำลังแข็งแกร่งขึ้น
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
ช่วงราคารายวัน
ปัจจุบัน US$36.13
ช่วง 52 สัปดาห์
ปัจจุบัน US$36.13
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 225.21M USD | 187.34M USD | 159.01M USD | 138.58M USD | 127.36M USD |
| ต้นทุนสินค้าขาย | 57.86M USD | 45.36M USD | 37.14M USD | 29.78M USD | 22.93M USD |
| กำไรขั้นต้น | 167.35M USD | 141.98M USD | 121.87M USD | 108.81M USD | 104.43M USD |
| การวิจัยและพัฒนา | 32.89M USD | 27.77M USD | 27.34M USD | 25.63M USD | 24.18M USD |
| การขาย ทั่วไป และธุรการ | 142.32M USD | 117.5M USD | 115.99M USD | 112.89M USD | 105.67M USD |
| ค่าใช้จ่ายในการดำเนินงาน | 175.2M USD | 145.26M USD | 143.33M USD | 138.52M USD | 129.84M USD |
| ดอกเบี้ยจ่าย | 7.7M USD | 8.21M USD | 2.84M USD | 624K USD | 1.36M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 8.19M USD | 7.84M USD | 5.55M USD | 4.85M USD | 4.74M USD |
| รายได้จากการดำเนินงาน | −7.85M USD | −3.29M USD | −21.46M USD | −29.71M USD | −25.42M USD |
| รายได้สุทธิ | −15.7M USD | −9.96M USD | −21.72M USD | −28.95M USD | −26.99M USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 11 ต.ค. 2569.
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$53.17
โอกาสปรับขึ้น 47.16%กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
Vanguard Morningstar Total Stock Market ETFVTI81.24M0.00%2.3T USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM50.79M0.06%78.74B USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF31.38M0.03%95.4B USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO17.67M0.13%13.92B USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO15.36M0.08%18B USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA11.24M0.05%21.82B USD0.03%US$32.79+0.40%
Fidelity Enhanced Small Cap ETFFESM11.04M0.17%6.41B USD0.28%US$45.46+0.46%
iShares U.S. Medical Devices ETFIHI10.5M0.30%3.57B USD0.37%US$51.74+1.25%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHA
Fidelity Enhanced Small Cap ETFFESM
iShares U.S. Medical Devices ETFIHIเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน